Dabigatran etexilate mesylat

An orally administered anticoagulant prodrug converted by esterases to dabigatran, a potent, competitive, reversible direct inhibitor of thrombin (factor IIa). It is used to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation and for the treatment and prevention of venous thromboembolism, including deep vein thrombosis and pulmonary embolism. Unlike vitamin K antagonists, dabigatran acts directly on thrombin and does not require routine INR monitoring

CAS Number: 872728-81-9

Molecular Mass: 723.8 g/mol

Formula: C₃₅H₄₅N₇O₈S

Smiles: CCCCCCOC(=O)NC(=N)c1ccc(NCc2nc3cc(C(=O)N(CCC(=O)OCC)c4ccccn4)ccc3n2C)cc1.CS(=O)(=O)O

Synonymes:

Dabigatran etexilate mesylat, Dabigatran etexilate mesylate, 872728-81-9, Dabigatran etexilate mesilate, Pradaxa, BIBR 1048 MS, SC7NUW5IIT, Dabigatran etexilate methanesulfonate, BIBR 1048MS, BIBR-1048-MS, PRADAXA (DABIGATRAN ETEXILATE MESYLATE), Ethyl 3-(((2-(((4-(((hexyloxy)carbonyl)carbamimidoyl)phenyl)amino)methyl)-1-methyl-1h-benzimidazol-5-yl)carbonyl)(pyridin-2-yl)amino)propanoate, methanesulfonate, beta-Alanine, N-((2-(((4-((((hexyloxy)carbonyl)amino)iminomethyl)phenyl)amino)methyl)-1-methyl-1h-benzimidazol-5-yl)carbonyl)-N-2-pyridinyl-, ethyl ester, methanesulfonate, 593282-20-3, CHEBI:70743, DTXSID20236248, RefChem:54925, DTXCID20158739, Beta-alanine, N-((2-(((4-((((hexyloxy)carbonyl)amino)iminomethyl) phenyl)amino)methyl)-1-methyl-1H-benzimidazol-5-yl)carbonyl)-N-2-pyridinyl-,ethyl ester, methanesulfonate, Pradaxa mesylate, Dabigatran etexilate (mesylate), Dabigatran etexilate mesylate [USAN], Dabigatran etexilate mesylate (USAN), UNII-SC7NUW5IIT, orb1302061, SCHEMBL1268805, CHEMBL1615369, SCHEMBL28563773, SCHEMBL29354679, SCHEMBL30487097, GLXC-08118, HMS5087O09, HY-10274AR, [14C]-Dabigatran etexilate mesylate, EBC-12905, HY-10274A, AKOS015951091, CS-1398, FD20773, SB19226, AC-26434, DABIGATRAN ETEXILATE (AS MESILATE), Dabigatran etexilate (mesylate) (Standard), DB-072628, Dabigatran etexilate mesilate [EP monograph], DABIGATRAN ETEXILATE MESILATE [MART.], (Z)-ethyl 3-(2-(((4-(N'-((hexyloxy)carbonyl)carbamimidoyl)phenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate methanesulfonate, DABIGATRAN ETEXILATE MESILATE [WHO-DD], D07082, DABIGATRAN ETEXILATE MESILATE [EMA EPAR], DABIGATRAN ETEXILATE MESYLATE [ORANGE BOOK], EN300-20384744, N-[[2-[[[4-[[[(hexyloxy)carbonyl]amino]iminomethy, Q27139056, Dabigatran Etexilate Mesylate Working Standard (Secondary Reference Standard), .BETA.-ALANINE, N-((2-(((4-((((HEXYLOXY)CARBONYL)AMINO)IMINOMETHYL)PHENYL)AMINO)METHYL)-1-METHYL-1H-BENZIMIDAZOL-5-YL)CARBONYL)-N-2-PYRIDINYL-, ETHYL ESTER, METHANESULFONATE, .BETA.-ALANINE, N-((2-(((4-((((HEXYLOXY)CARBONYL)AMINO)IMINOMETHYL)PHENYL)AMINO)METHYL)-1-METHYL-1H-BENZIMIDAZOL-5-YL)CARBONYL)-N-2-PYRIDINYL-, ETHYL ESTER, METHANESULFONATE (1:1), .BETA.-ALANINE, N-((2-(((4-((((HEXYLOXY)CARBONYL)AMINO)IMINOMETHYL)PHENYL)AMINO)METHYL)-1-METHYL-1H-BENZIMIDAZOL-5-YL)CARBONYL)-N-2-PYRIDINYL-, ETHYL ESTER, METHANESULPHONATE, .BETA.-ALANINE, N-((2-(((4-((((HEXYLOXY)CARBONYL)AMINO)IMINOMETHYL)PHENYL)AMINO)METHYL)-1-METHYL-1H-BENZIMIDAZOL-5-YL)CARBONYL)-N-2-PYRIDINYL-, ETHYL ESTER, METHANESULPHONATE (1:1), BIBR 1048, BIBR-1048, Prazaxa, ethyl 3-(2-(((4-(N-((hexyloxy)carbonyl)carbamimidoyl)phenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate methanesulfonate, ETHYL 3-(((2-(((4-(((HEXYLOXY)CARBONYL)CARBAMIMIDOYL)PHENYL)AMINO)METHYL)-1-METHYL-1H-BENZIMIDAZOL-5-YL)CARBONYL)(PYRIDIN-2-YL)AMINO)PROPANOATE, METHANESULPHONATE, ethyl 3-[[2-[[4-(N-hexoxycarbonylcarbamimidoyl)anilino]methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoate, methanesulfonic acid, ethyl 3-[[2-[[4-[(E)-N'-hexoxycarbonylcarbamimidoyl]anilino]methyl]-1-methyl-benzimidazole-5-carbonyl]-(2-pyridyl)amino]propanoate, methanesulfonic acid, ethyl 3-{1-[2-({[4-({[(hexyloxy)carbonyl]amino}methanimidoyl)phenyl]amino}methyl)-1-methyl-1H-1,3-benzodiazol-5-yl]-N-(pyridin-2-yl)formamido}propanoate, methanesulfonic acid, N-[[2-[[[4-[[[(Hexyloxy)carbonyl]aMino]iMinoMethyl]phenyl]aMino]Methyl]-1-Methyl-1H-benziMidazol-5-y, N-[[2-[[[4-[[[(Hexyloxy)carbonyl]amino]iminomethyl]phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-b-alan ine ethyl ester methanesulfonate

Bioactivity: Direct thrombin (factor IIa) inhibitor prodrug; oral anticoagulant

Solubility in Different Solvents

Solvent	Temperature [K]	Crystal form	Solubility [mg/mL]	Reference
Dimethylacetamide	287.37	-	183.4	[94]
Dimethylacetamide	292.2	-	193.2	[94]
Dimethylacetamide	297.95	-	211.0	[94]
Dimethylacetamide	303.97	-	226.9	[94]
Dimethylacetamide	308.88	-	247.0	[94]
Dimethylacetamide	313.59	-	268.0	[94]
Dimethylacetamide	318.4	-	294.5	[94]
Dimethylacetamide	323.39	-	318.5	[94]
Dimethylformamide	287.37	-	209.6	[94]
Dimethylformamide	292.2	-	220.4	[94]
Dimethylformamide	297.95	-	235.8	[94]
Dimethylformamide	303.97	-	256.9	[94]
Dimethylformamide	308.88	-	280.0	[94]
Dimethylformamide	313.59	-	302.2	[94]
Dimethylformamide	318.4	-	332.0	[94]
Dimethylformamide	323.39	-	364.6	[94]
Ethanol	287.37	-	11.5	[94]
Ethanol	292.2	-	14.42	[94]
Ethanol	297.95	-	18.91	[94]
Ethanol	303.97	-	25.55	[94]
Ethanol	308.88	-	32.63	[94]
Ethanol	313.59	-	41.73	[94]
Ethanol	318.4	-	55.48	[94]
Ethanol	323.39	-	75.53	[94]
Ethylene Glycol	287.37	-	55.61	[94]
Ethylene Glycol	292.2	-	68.42	[94]
Ethylene Glycol	297.95	-	80.61	[94]
Ethylene Glycol	303.97	-	102.1	[94]
Ethylene Glycol	308.88	-	124.7	[94]
Ethylene Glycol	313.59	-	145.1	[94]
Ethylene Glycol	318.4	-	185.3	[94]
Ethylene Glycol	323.39	-	232.1	[94]
Methanol	287.37	-	288.8	[94]
Methanol	292.2	-	328.0	[94]
Methanol	297.95	-	407.1	[94]
Methanol	303.97	-	496.9	[94]
Methanol	308.88	-	603.9	[94]
Methanol	313.59	-	705.5	[94]
Methanol	318.4	-	856.5	[94]
Methanol	323.39	-	1000.0	[94]

Molecule 3D descriptors

Descriptor	Value
PMI1	5719.0069
PMI2	27759.7524
PMI3	29026.9118
NPR1	0.1970
NPR2	0.9563
RadiusOfGyration	6.5708
InertialShapeFactor	0.0002
Eccentricity	0.9804
Asphericity	0.5276
SpherocityIndex	0.2187
PBF	1.5193